Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / OTLK - Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market

OTLK - Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market

Outlook Therapeutics Inc.

2024-06-13 05:50:39 ET

Summary

  • Outlook Therapeutics is resubmitting a BLA for ONS-5010 by 2024, with top-line data expected in Q4, 2024.
  • ONS-5010 received European Commission Marketing Authorization for treating wet AMD in May 2024, and it is preparing for a commercial launch in early 2025.
  • The anti-VEGF retina market is estimated at $15.9 billion globally, with substantial market opportunities in the US, EU, and UK.
  • I deem OTLK stock a speculative buy due to its substantial upside potential, assuming successful FDA approval and market launch. I believe the risks are justified, given its considerable upside potential.

...

For further details see:

Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market
Stock Information
Company Name: Outlook Therapeutics Inc.
Stock Symbol: OTLK
Market: NASDAQ
Website: outlooktherapeutics.com
Menu
OTLK OTLK Quote OTLK Short OTLK News OTLK Articles OTLK Message Board
Get OTLK Alerts

News, Short Squeeze, Breakout and More Instantly...